---
figid: PMC7913382__jcm-10-00566-g004
figlink: pmc/articles/PMC7913382/figure/jcm-10-00566-f004/
number: F4
caption: Overview of STAT3 activation via the JAK-STAT pathway (cytokine and growth
  factor receptor stimulation) and cytoplasmic Src kinase. A JAK inhibitor (ruxolitinib),
  STAT3 inhibitors (danvatirsen, napabucasin) and a Src inhibitor (dasatinib) are
  currently in clinical trials for pancreatic cancer.
pmcid: PMC7913382
papertitle: The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic
  Cancer Therapies.
reftext: Andres Garcia-Sampedro, et al. J Clin Med. 2021 Feb;10(4):566.
pmc_ranked_result_index: '33276'
pathway_score: 0.9570572
filename: jcm-10-00566-g004.jpg
figtitle: STAT3 activation via the JAK-STAT pathway (cytokine and growth factor receptor
  stimulation) and cytoplasmic Src kinase
year: '2021'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7913382__jcm-10-00566-g004.html
  '@type': Dataset
  description: Overview of STAT3 activation via the JAK-STAT pathway (cytokine and
    growth factor receptor stimulation) and cytoplasmic Src kinase. A JAK inhibitor
    (ruxolitinib), STAT3 inhibitors (danvatirsen, napabucasin) and a Src inhibitor
    (dasatinib) are currently in clinical trials for pancreatic cancer.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - SRC
  - STAT3
  - Ruxolitinib
  - tyrosine
  - Dasatinib
genes:
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK1
  entrez: '3716'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK2
  entrez: '3717'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK3
  entrez: '3718'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: TYK2
  entrez: '7297'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK1
  entrez: '3716'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK2
  entrez: '3717'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK3
  entrez: '3718'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: TYK2
  entrez: '7297'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK1
  entrez: '3716'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK2
  entrez: '3717'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK3
  entrez: '3718'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: TYK2
  entrez: '7297'
- word: Src
  symbol: SRC
  source: hgnc_symbol
  hgnc_symbol: SRC
  entrez: '6714'
- word: STAT3
  symbol: STAT3
  source: hgnc_symbol
  hgnc_symbol: STAT3
  entrez: '6774'
- word: STAT3
  symbol: STAT3
  source: hgnc_symbol
  hgnc_symbol: STAT3
  entrez: '6774'
- word: STAT3
  symbol: STAT3
  source: hgnc_symbol
  hgnc_symbol: STAT3
  entrez: '6774'
- word: STAT3
  symbol: STAT3
  source: hgnc_symbol
  hgnc_symbol: STAT3
  entrez: '6774'
chemicals:
- word: Ruxolitinib
  source: MESH
  identifier: C540383
- word: tyrosine
  source: ''
  identifier: ''
- word: Dasatinib
  source: MESH
  identifier: C488369
diseases: []
figid_alias: PMC7913382__F4
redirect_from: /figures/PMC7913382__F4
figtype: Figure
---
